Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

On January 16, 2020, the board of directors of Ekso Bionics Holdings, Inc. (the "Company") approved grants of equity awards to Steven Sherman, a named executive officer of the Company, in respect of his continued service as the Company's Executive Chairman. These awards were made pursuant to the Company's Amended and Restated 2014 Stock Incentive Plan, and consisted of options to purchase 250,000 shares of the Company's common stock and 200,000 restricted stock units. The option award becomes exercisable as to 31,250 shares on each of March 31, 2020 and the last day of each third month thereafter. The restricted stock units vest as to 25,000 shares on each of March 31, 2020 and the last day of each third month thereafter, and will settle upon Mr. Sherman's separation of service from the Company.

All compensation for the Company's names executive officers for the fiscal year ended December 31, 2019 will be reported by the Company in the Summary Compensation Table in the Company's Annual Report on Form 10-K for the year ending December 31, 2019 or its proxy statement relating to the Company's next annual meeting of stockholders, to be filed with the Securities and Exchange Commission no later than 120 days after December 31, 2019, or in an earlier report or proxy statement filed with the Securities and Exchange Commission.

© Edgar Online, source Glimpses